Literature DB >> 9503777

Prevalence of hepatitis B and C virus markers in outpatients of Mongolian general hospitals.

S Fujioka1, H Shimomura, Y Ishii, J Kondo, K Fujio, F Ikeda, M Miyake, S Kusachi, T Tsuji.   

Abstract

In East Asian countries, the prevalence of viral hepatitis has been reported to be high, but precise data for each country remained to be investigated. Here we report the prevalence of viral markers of hepatitis B and hepatitis C in outpatient volunteers visiting two general hospitals in Ulaanbaatar, Mongolia. One hundred fifty sera were tested for HBs antigen (HBsAg), anti-HBs, and anti-HCV by Counting Immunoassay. The backgrounds of groups of patients positive for HBsAg and negative for anti-HCV (group 1; n = 18), negative for HBsAg and positive for anti-HCV (group 2; n = 47), positive for both HBsAg and anti-HCV (group 3; n = 25), and negative for both HBsAg and anti-HCV (group 4; n = 60) were compared. The prevalence of HBsAg, anti-HBs, and anti-HCV in this study group was 28.7%, 39.3% and 48.0%, respectively. Subjects of group 1 (mean +/- SD; 31.3 +/- 12.4 years old) were younger than those of group 4 (39.2 +/- 14.3; p < 0.05), while patients of group 2 (48.7 +/- 15.5) were older than those of group 4 (p < 0.01). More group 2 subjects had histories of jaundice (23/47) than those of group 4 (15/60; p < 0.05). Transaminase levels were higher in group 1 (median (range) IU/l of AST, ALT; 29 (13-95), 32 (9-144) and group 3 (25 (15-187), 22 (8-185)) than in group 4 (18 (9-13), 15 (6-133); p < 0.05, p < 0.005 vs. group 1, and p < 0.005, p < 0.001 vs. group 3, respectively). In HBsAg-negative subjects, those with higher titers of anti-HCV (cut-off index > 15) were older, and had more histories of jaundice and higher levels of AST and ALT than anti-HCV negative subjects (50.3 +/- 14.8 vs. 39.1 +/- 14.3, p < 0.01; 15/28 vs. 15/60, p < 0.01; 22.5 (12-127) vs. 18 (9-93), p < 0.05; 20.5 (7-362) vs. 15 (6-133), p < 0.05; respectively). In conclusion, this preliminary surveillance for hepatitis B and C viral markers showed that both hepatitis viruses are prevalent and may cause liver diseases in Mongolia. A nation-wide survey for these viruses should be urged and preventive measures should be taken to suppress the spread and development of liver diseases in this country.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9503777     DOI: 10.11150/kansenshogakuzasshi1970.72.5

Source DB:  PubMed          Journal:  Kansenshogaku Zasshi        ISSN: 0387-5911


  5 in total

1.  Administration of hepatitis B vaccine in winter as a significant predictor of the poor effectiveness of vaccination in rural Mongolia: evidence from a nationwide survey.

Authors:  Dambadarjaa Davaalkham; Toshiyuki Ojima; Steven Wiersma; Tserenkhuu Lkhagvasuren; Pagvajav Nymadawa; Ritei Uehara; Makoto Watanabe; Izumi Oki; Yosikazu Nakamura
Journal:  J Epidemiol Community Health       Date:  2007-07       Impact factor: 3.710

2.  High prevalence of antibodies to hepatitis A and E viruses and viremia of hepatitis B, C, and D viruses among apparently healthy populations in Mongolia.

Authors:  Masaharu Takahashi; Tsutomu Nishizawa; Yuhko Gotanda; Fumio Tsuda; Fumio Komatsu; Terue Kawabata; Kyoko Hasegawa; Murdorjyn Altankhuu; Ulziiburen Chimedregzen; Luvsanbasaryn Narantuya; Hiromi Hoshino; Kunihiko Hino; Yasuo Kagawa; Hiroaki Okamoto
Journal:  Clin Diagn Lab Immunol       Date:  2004-03

Review 3.  Emerging infectious diseases in Mongolia.

Authors:  John R Ebright; Togoo Altantsetseg; Ravdan Oyungerel
Journal:  Emerg Infect Dis       Date:  2003-12       Impact factor: 6.883

Review 4.  Viral Hepatitis in Mongolia: Past, Present, and Future.

Authors:  Bira Tsatsralt-Od
Journal:  Euroasian J Hepatogastroenterol       Date:  2016-07-09

5.  Impact of the universal hepatitis B immunization program in Mongolia: achievements and challenges.

Authors:  Dambadarjaa Davaalkham; Toshiyuki Ojima; Ritei Uehara; Makoto Watanabe; Izumi Oki; Steven Wiersma; Pagvajav Nymadawa; Yosikazu Nakamura
Journal:  J Epidemiol       Date:  2007-05       Impact factor: 3.211

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.